- Report
- August 2025
- 270 Pages
Global
From €5174EUR$5,850USD£4,467GBP
- Report
- August 2025
- 507 Pages
Global
From €5174EUR$5,850USD£4,467GBP
- Report
- August 2025
- 620 Pages
Global
From €5174EUR$5,850USD£4,467GBP
- Report
- August 2025
- 194 Pages
Global
From €5174EUR$5,850USD£4,467GBP
- Report
- May 2025
- 146 Pages
Global
From €2652EUR$2,999USD£2,290GBP
- Report
- April 2025
- 135 Pages
Global
From €2652EUR$2,999USD£2,290GBP
- Report
- January 2025
- 128 Pages
Global
From €2652EUR$2,999USD£2,290GBP
- Report
- June 2025
- 150 Pages
Global
From €3316EUR$3,750USD£2,863GBP
- Report
- December 2024
- 30 Pages
Global
From €2432EUR$2,750USD£2,100GBP
- Report
- August 2025
- 150 Pages
Global
From €3493EUR$3,950USD£3,016GBP
- Report
- May 2025
- 140 Pages
Global
From €2795EUR$3,160USD£2,413GBP
€3493EUR$3,950USD£3,016GBP
- Report
- June 2025
- 400 Pages
Global
From €4377EUR$4,949USD£3,779GBP
- Report
- June 2025
- 400 Pages
Global
From €4377EUR$4,949USD£3,779GBP
- Report
- August 2024
- 200 Pages
Global
From €3422EUR$3,869USD£2,954GBP
- Report
- April 2025
- 106 Pages
Global
From €3500EUR$4,240USD£3,128GBP
- Report
- July 2025
- 217 Pages
Global
From €4417EUR$4,995USD£3,814GBP
- Report
- April 2025
- 215 Pages
Global
From €3980EUR$4,500USD£3,436GBP
- Report
- January 2024
- 348 Pages
Global
From €5215EUR$6,103USD£4,350GBP
- Report
- December 2022
- 354 Pages
Global
From €4735EUR$5,542USD£3,950GBP
- Report
- November 2022
- 148 Pages
Global
From €4864EUR$5,500USD£4,199GBP

The Dry Powder Inhaler (DPI) market is a segment of the respiratory drugs market. It is a device used to deliver medication to the lungs in the form of a dry powder. It is a convenient and efficient way to deliver medication to the lungs, as it does not require the use of a propellant gas. DPIs are used to treat a variety of respiratory conditions, such as asthma, chronic obstructive pulmonary disease (COPD), and cystic fibrosis. They are also used to deliver vaccines and other medications.
DPIs are becoming increasingly popular due to their convenience and effectiveness. They are also cost-effective, as they require fewer components than other inhalers. Additionally, DPIs are easy to use and can be used by patients of all ages.
Several companies are involved in the DPI market, including GlaxoSmithKline, Boehringer Ingelheim, Novartis, Merck, and AstraZeneca. These companies are involved in the development, manufacture, and marketing of DPIs. Show Less Read more